Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03844113
Registration number
NCT03844113
Ethics application status
Date submitted
12/02/2019
Date registered
18/02/2019
Titles & IDs
Public title
Carnosine for Peripheral Vascular Disease
Query!
Scientific title
Carnosine for Peripheral Vascular Disease
Query!
Secondary ID [1]
0
0
Car-PVD
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Car-PVD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Carnosine
Treatment: Drugs - Placebo
Active comparator: Intervention - Each participant will be given a daily oral dose 2 g of carnosine for 6 months
Placebo comparator: Control - Each participant will be given a daily oral dose 2 g of placebo for 6 months
Treatment: Drugs: Carnosine
Each participant will be given a daily oral dose 2 g of carnosine for 6 months
Treatment: Drugs: Placebo
Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
walking endurance
Query!
Assessment method [1]
0
0
change in walking endurance (6-min walk test)
Query!
Timepoint [1]
0
0
6 months
Query!
Eligibility
Key inclusion criteria
* Age >=40or <80 years
* Clinical diagnosis Peripheral Vascular disease
* Rutherford Grade 1-3
* No significant kidney, cardiovascular, haematological, respiratory, gastrointestinal, or central nervous system disease, as well as no psychiatric disorders, no active cancer within the last five years; no presence of acute inflammation (by history, physical or laboratory examination)
* Intermittent claudication on treadmill between 30m and 200m
* Ankle Brachial index 0.6-1 at rest with minimum post exercise drop in ABI of 0.1
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Age < 40 or > 80 years
* Pregnant or lactating
* Limb threatening ischaemia- Rutherford grades 4-6, manifested by ischaemic rest pain, ulceration, or gangrene; acute limb-threatening ischaemia
* lower limb surgical or endovascular interventions in the preceding 6 months
* planned lower limb endovascular or surgical intervention within the next 6 months on either limb
* taking medication for PVD (Cilostazol and Pentoxifylline)
* inability to complete the treadmill walking test for reasons other than claudication
* myocardial infarction within last 3 months
* deep vein thrombosis within 3 months
* estimated life expectancy < 1 year
* alcohol and illicit drug abuse.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
UNKNOWN
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2022
Query!
Actual
Query!
Sample size
Target
104
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Monash Centre for Health Research and Implementation - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3168 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Monash University
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Monash Health
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The investigators hypothesise that a home-based standardised exercise intervention with 2g of carnosine daily for 6 months will improve walking endurance in 104 patients with PVD aged 40-80 years compared to placebo and exercise through stabilisation of HIF1-a in the ischaemic leg. Aims Aim 1: Determine whether in patients with PVD, carnosine in addition to exercise improves: 1. walking endurance (6-min walk test; primary outcome); 2. initial claudication distance (ICD), and absolute claudication distance (ACD; treadmill), cadence, resting and exercise ABI; and 3. central blood pressure, endothelial function, arterial (aortic) stiffness, lipid profile; and 4. quality of life as determined by EuroQol-5D (all secondary outcomes). 5. Improve cognitive function (global cognitive score formed by a composite of 7 cognitive tests) Aim 2: Delineate the mechanisms by which carnosine improves walking endurance: 1. protein expression of pro-angiogenic and carnosine related genes, including carnosine transporters in the skeletal muscle biopsies, EPCs in peripheral blood and quantitative proteomic studies. 2. other mechanisms demonstrated in animal studies including plasma inflammatory markers, serum and urinary advanced glycation (AGE) and lipoxidation (ALE) end-products (tertiary outcomes). This trial will provide evidence for use of carnosine as a therapeutic intervention for PVD patients and, if positive, will have immediate clinical application.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03844113
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Barbora deCourten, MD,PHD,MPH
Query!
Address
0
0
Monash University and Monash Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Barbora deCourten, MD,PHD,MPH
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+610385722651
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03844113